On Friday, Shares of Prima Biomed Ltd. (NASDAQ:PBMD), skyrocketed 44% to $1.44.
Prima BioMed declared it will receive an unrevealed clinical milestone payment from its partnership and licensing agreement with Novartis regarding its Phase I IMP701 LAG-3 antibody. The antibody is being trialled for the treatment of cancer.
Immutep (which Prima Biomed attained in December 2014) and CoStim Pharmaceuticals (which Novartis attained in February 2014) reached a commercial licensing and partnership agreement in September 2012, under which CoStim obtained a licence to develop and commercialize antagonistic LAG-3 antibodies.
Novartis has full responsibility for the continued development of the antibody program and Prima is eligible to receive further potential development-based milestone payments and royalties on sales following commercialization of the products.
Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer.
Shares of JetBlue Airways Corporation (NASDAQ:JBLU), inclined 0.76% to $24, during its last trading session, hitting its highest level.
JetBlue Airways Corporation stated its preliminary traffic results for July 2015. Traffic in July raised 8.9 percent from July 2014, on a capacity enhance of 10.4 percent.
Load factor for July 2015 was 87.0 percent, a decrease of 1.3 points from July 2014. JetBlue’s preliminary completion factor was 99.1 percent and its on-time (1) performance was 76.5 percent. JetBlue’s preliminary passenger revenue per accessible seat mile for the month of July raised about one percent year over year.
JetBlue Airways Corporation, a passenger carrier company, provides air transportation services. As of December 31, 2014, the company operated a fleet of 13 Airbus A321 aircrafts, 130 Airbus A320 aircrafts, and 60 EMBRAER 190 aircrafts.
Finally, Bristow Group, Inc. (NYSE:BRS), ended its last trade with -0.03% loss, and closed at $39.91, hitting its lowest level.
Bristow Group stated a net loss for the June 2015 quarter of $3.3 million, or $0.27 per diluted share on a GAAP basis, contrast to net income of $44.1 million, or $1.23 per diluted share, in the same period in the preceding year.
Adjusted net income, which excludes special items and asset disposition effects, reduced 58% to $19.8 million, or $0.56 per diluted share, for the June 2015 quarter, contrast to $47.4 million, or $1.32 per diluted share, in the June 2014 quarter.
Adjusted earnings before interest, taxes, depreciation, amortization and rent, which also excludes special items and asset disposition effects, reduced 5% to $121.0 million for the June 2015 quarter contrast to $127.6 million in the same period in the preceding year. Net cash offered by operating activities was $15.9 million for the June 2015 quarter contrast to $37.3 million for the preceding year period.
Bristow Group Inc. provides helicopter services to the offshore energy industry in Africa, Americas, the Asia Pacific, and Europe Caspian. Its helicopters are used principally to transport personnel between onshore bases and offshore production platforms, drilling rigs, and other installations, in addition to transport time-sensitive equipment to these offshore locations.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
